1. Show article details.

    China NMPA Approves PARP Inhibitor Pamiparib for Patients with Previously Treated Advanced Ovarian Cancer

    Business Wire – 12:00 AM ET 05/07/2021

    Pamiparib becomes the first PARP inhibitor approved in both platinum-sensitive and platinum-resistant relapsed ovarian cancer in China This marks the first approval of pamiparib and the third BeiGene-discovered medicine to receive regulatory approval BEIJING & CAMBRIDGE, Mass.

  2. Show article details.

    BeiGene Reports First Quarter 2021 Financial Results

    Business Wire – 4:05 PM ET 05/06/2021

    CAMBRIDGE, Mass.

  3. Show article details.

    BRUKINSA® (Zanubrutinib) Demonstrates Superior Objective Response Rate by Investigator Assessment and Reduced Rates of Atrial Fibrillation or Flutter at Interim Analysis in Head-to-Head Trial Against Ibrutinib in Chronic Lymphocytic Leukemia

    Business Wire – 7:00 AM ET 04/28/2021

    BeiGene (BGNE) announced positive results from a planned interim analysis of the Phase 3 ALPINE trial comparing BRUKINSA® against ibrutinib in adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

  4. Show article details.

    BeiGene Presents Interim Analysis Results of RATIONALE 303 Trial of Tislelizumab in Second- or Third-Line Non-Small Cell Lung Cancer at the AACR Annual Meeting 2021

    Business Wire – 1:30 PM ET 04/12/2021

    CAMBRIDGE, Mass.

  5. Show article details.

    BeiGene Presents Clinical Data on Sitravatinib in Combination with Tislelizumab at the AACR Annual Meeting 2021

    Business Wire – 4:00 PM ET 04/11/2021

    CAMBRIDGE, Mass. BeiGene (BGNE) has an exclusive collaboration and license agreement with Mirati for the development, manufacturing and commercialization of sitravatinib in Asia, Australia, and New Zealand.

  6. Show article details.

    BeiGene Launches BRUKINSA® (Zanubrutinib) in Canada for Patients with Waldenström’s Macroglobulinemia

    Business Wire – 7:00 AM ET 04/08/2021

    BeiGene, Ltd. (BGNE), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced the official launch of BRUKINSA® in Canada for the treatment of adult patients with Waldenström’s macroglobulinemia.

  7. Show article details.

    BeiGene Provides Update on Phase 2 Clinical Trial of Zanubrutinib in Patients with COVID-19-Related Pulmonary Distress

    Business Wire – 7:00 AM ET 04/08/2021

    Trial did not meet the co-primary efficacy endpoints; no new safety signals identified BeiGene, Ltd. (BGNE), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the Phase 2 trial evaluating BRUKINSA® in patients hospitalized with respiratory symptoms of COVID-19, requiring supplemental oxygen without mechanical ventilation, did...

  8. Show article details.

    BeiGene Announces First Commercial Manufacturing Approval for Its State-of-the-Art Biologics Facility in Guangzhou, China

    Business Wire – 7:00 PM ET 04/07/2021

    Commercial supply of tislelizumab for China now expanded with wholly owned manufacturing site BeiGene, Ltd. (BGNE), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced approval from the China National Medical Products Administration for BeiGene (BGNE) to begin manufacturing commercial supply of its approved anti-PD-1 antibody, tis...

  9. Show article details.

    BeiGene Announces New Chief Financial Officer, Julia Wang

    Business Wire – 8:30 AM ET 03/30/2021

    Current CFO and Chief Strategy Officer Howard Liang, Ph.D. to Retire from BeiGene (BGNE) in June BeiGene (BGNE), Ltd., a global biotechnology company focused on developing and commercializing innovative medicines, today announced that Julia Wang has been appointed as Chief Financial Officer, effective June 30, 2021. This press release features multimedia.

  10. Show article details.

    111, Inc. Enters into First-Ever Strategic Partnership with BeiGene

    PR Newswire – 6:50 AM ET 03/17/2021

    SHANGHAI, March 17, 2021 111, Inc. (YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, announced today it has entered into a strategic cooperation agreement with BeiGene, Ltd. (BGNE), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide.

  11. Show article details.

    BeiGene Announces Presentation of Clinical and Preclinical Data at the AACR Annual Meeting 2021

    Business Wire – 4:30 PM ET 03/10/2021

    BeiGene, Ltd. (BGNE), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced multiple presentations at the American Association for Cancer Research Annual Meeting 2021, including three oral presentations to highlight clinical data on anti-PD-1 antibody tislelizumab and on investigational spectrum-selective kinase inhibitor sit...

  12. Show article details.

    BeiGene Initiates Phase 1 Clinical Trial for HPK1 Inhibitor BGB-15025

    Business Wire – 7:00 AM ET 03/10/2021

    BeiGene, Ltd. (BGNE), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the first patient has been dosed in a Phase 1 clinical trial of BGB-15025, its investigational hematopoietic progenitor kinase 1 inhibitor.

  13. Show article details.

    BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Second- or Third-line Non-Small Cell Lung Cancer

    Business Wire – 8:30 AM ET 03/05/2021

    BeiGene, Ltd. (BGNE), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that a supplemental Biologics License Application for anti-PD1 antibody tislelizumab was accepted by the Center for Drug Evaluation of the China National Medical Products Administration for treatment in the second- or third-line setting of patients wi...

  14. Show article details.

    Health Canada Approves BRUKINSA® (Zanubrutinib) for the Treatment of Waldenström’s Macroglobulinemia

    Business Wire – 7:00 AM ET 03/02/2021

    BeiGene, Ltd. (BGNE), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that BRUKINSA® has been approved by Health Canada for the treatment of adult patients with Waldenström’s macroglobulinemia.

  15. Show article details.

    Health Canada Approves BRUKINSA® (Zanubrutinib) for the Treatment of Waldenström’s Macroglobulinemia

    Business Wire – 7:00 AM ET 03/02/2021

    BeiGene, Ltd. (BGNE), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that BRUKINSA® has been approved by Health Canada for the treatment of adult patients with Waldenström’s macroglobulinemia.

  16. Show article details.

    Novartis to Co-Develop Cancer Drug With China's BeiGene

    DJ Business News – 7:33 AM ET 02/26/2021

    Novartis AG (NVS) said Friday that it will co-develop cancer drug tislelizumab with China-based pharmaceutical company BeiGene (BGNE) as part of an in-licensing agreement. The Swiss pharma giant said it will initiate additional clinical trials to study the drug's efficacy on different types of cancer, as tislelizumab is now only approved in China for patients with non-small cell lung cancer, classical Hodgkin's lymphoma and metastatic urothelial carcinoma. The agreement--the...

  17. Show article details.

    BeiGene Announces Closing of Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab in North America, Europe and Japan

    Business Wire – 7:00 AM ET 02/26/2021

    BeiGene, Ltd. (BGNE), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced the closing of the collaboration and license agreement with Novartis Pharma AG, previously announced on January 11, 2021, to develop, manufacture, and commercialize BeiGene’s anti-PD-1 antibody tislelizumab in the United States, Canada, Mexico, memb...

  18. Show article details.

    BeiGene Reports Fourth Quarter and Full Year 2020 Financial Results

    Business Wire – 4:05 PM ET 02/25/2021

    BeiGene, Ltd. (BGNE), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today reported recent business highlights, anticipated upcoming milestones, and financial results for the fourth quarter and full year of 2020.

  19. Show article details.

    Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 Antagonists

    Business Wire – 5:00 PM ET 02/17/2021

    Exclusive license for Asia, Australia and New Zealand; Parties plan to conduct combination studies with BeiGene's (BGNE) anti-PD-1 antibody tislelizumab Boston Immune Technologies and Therapeutics, Inc., a privately held developer of novel antagonist antibodies for cancer and other diseases, and BeiGene, Ltd. (BGNE) today announced that they have entered into an option and license agreement aimed at developi...

  20. Show article details.

    BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (Zanubrutinib) in Waldenström’s Macroglobulinemia

    Business Wire – 7:00 AM ET 02/17/2021

    BeiGene, Ltd. (BGNE), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the U.S. Food and Drug Administration has accepted a supplemental new drug application for BRUKINSA® for the treatment of adult patients with Waldenström’s Macroglobulinemia.

Page:

Today's and Upcoming Events

No events in the next 90 days

Past Events (last 90 days)

  • Feb
    25

    BGNE announced Q4 earnings.

Data provided by Thomson Reuters © 2021

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.